Kurs & Likviditet
Kalender
2024-02-08 | Bokslutskommuniké 2023 |
2023-11-09 | Kvartalsrapport 2023-Q3 |
2023-07-28 | Kvartalsrapport 2023-Q2 |
2023-04-27 | Årsstämma 2023 |
2023-04-27 | Kvartalsrapport 2023-Q1 |
2023-02-23 | Halvårsutdelning AZN 20.69 |
2023-02-09 | Bokslutskommuniké 2022 |
2022-11-10 | Kvartalsrapport 2022-Q3 |
2022-08-11 | Halvårsutdelning AZN 9.49 |
2022-07-29 | Kvartalsrapport 2022-Q2 |
2022-04-29 | Kvartalsrapport 2022-Q1 |
2022-04-29 | Årsstämma 2022 |
2022-02-24 | Halvårsutdelning AZN 18 |
2022-02-10 | Bokslutskommuniké 2021 |
2021-11-12 | Kvartalsrapport 2021-Q3 |
2021-08-12 | Halvårsutdelning AZN 7.72 |
2021-07-29 | Kvartalsrapport 2021-Q2 |
2021-05-11 | Årsstämma 2021 |
2021-04-30 | Kvartalsrapport 2021-Q1 |
2021-02-25 | Halvårsutdelning AZN 15.76 |
2021-02-11 | Bokslutskommuniké 2020 |
2020-11-05 | Kvartalsrapport 2020-Q3 |
2020-08-13 | Halvårsutdelning AZN 7.87 |
2020-07-30 | Kvartalsrapport 2020-Q2 |
2020-04-29 | Årsstämma 2020 |
2020-04-29 | Kvartalsrapport 2020-Q1 |
2020-02-27 | Halvårsutdelning AZN 18.32 |
2020-02-14 | Bokslutskommuniké 2019 |
2019-10-24 | Kvartalsrapport 2019-Q3 |
2019-08-08 | Halvårsutdelning AZN 8.49 |
2019-07-25 | Kvartalsrapport 2019-Q2 |
2019-04-26 | Kvartalsrapport 2019-Q1 |
2019-04-26 | Årsstämma 2019 |
2019-02-28 | Halvårsutdelning AZN 17.46 |
2019-02-14 | Bokslutskommuniké 2018 |
2018-11-08 | Kvartalsrapport 2018-Q3 |
2018-08-09 | Halvårsutdelning AZN 7.92 |
2018-07-26 | Kvartalsrapport 2018-Q2 |
2018-05-18 | Årsstämma 2018 |
2018-05-18 | Kvartalsrapport 2018-Q1 |
2018-02-15 | Halvårsutdelning AZN 14.97 |
2018-02-02 | Bokslutskommuniké 2017 |
2017-11-09 | Kvartalsrapport 2017-Q3 |
2017-08-10 | Halvårsutdelning AZN 7.4 |
2017-07-27 | Kvartalsrapport 2017-Q2 |
2017-04-27 | Årsstämma 2017 |
2017-04-27 | Kvartalsrapport 2017-Q1 |
2017-02-16 | Halvårsutdelning AZN 16.57 |
2017-02-02 | Bokslutskommuniké 2016 |
2016-11-10 | Kvartalsrapport 2016-Q3 |
2016-08-11 | Halvårsutdelning AZN 7.81 |
2016-07-28 | Kvartalsrapport 2016-Q2 |
2016-04-29 | Årsstämma 2016 |
2016-04-29 | Kvartalsrapport 2016-Q1 |
2016-02-18 | Halvårsutdelning AZN 16.26 |
2016-02-04 | Bokslutskommuniké 2015 |
2015-11-05 | Kvartalsrapport 2015-Q3 |
2015-08-13 | Halvårsutdelning AZN 7.71 |
2015-07-30 | Kvartalsrapport 2015-Q2 |
2015-04-24 | Kvartalsrapport 2015-Q1 |
2015-04-24 | Årsstämma 2015 |
2015-02-19 | Halvårsutdelning AZN 15.62 |
2015-02-05 | Bokslutskommuniké 2014 |
2014-11-06 | Kvartalsrapport 2014-Q3 |
2014-08-13 | Halvårsutdelning AZN 6.2 |
2014-07-31 | Kvartalsrapport 2014-Q2 |
2014-04-24 | Kvartalsrapport 2014-Q1 |
2014-04-24 | Årsstämma 2014 |
2014-02-19 | Halvårsutdelning AZN 12.41 |
2014-02-06 | Bokslutskommuniké 2013 |
2013-10-31 | Kvartalsrapport 2013-Q3 |
2013-08-14 | Halvårsutdelning AZN 5.92 |
2013-08-01 | Kvartalsrapport 2013-Q2 |
2013-08-01 | Analytiker möte 2013 |
2013-04-25 | Kvartalsrapport 2013-Q1 |
2013-04-25 | Årsstämma 2013 |
2013-02-13 | Halvårsutdelning AZN 12.08 |
2013-01-31 | Bokslutskommuniké 2012 |
2012-10-25 | Kvartalsrapport 2012-Q3 |
2012-10-25 | Analytiker möte 2012 |
2012-08-08 | Halvårsutdelning AZN 6.26 |
2012-07-26 | Kvartalsrapport 2012-Q2 |
2012-04-26 | Årsstämma 2012 |
2012-04-26 | Kvartalsrapport 2012-Q1 |
2012-02-15 | Halvårsutdelning AZN 13.21 |
2012-02-02 | Bokslutskommuniké 2011 |
2011-10-27 | Kvartalsrapport 2011-Q3 |
2011-08-03 | Halvårsutdelning AZN 5.33 |
2011-07-28 | Kvartalsrapport 2011-Q2 |
2011-04-28 | Årsstämma 2011 |
2011-04-28 | Kvartalsrapport 2011-Q1 |
2011-02-02 | Halvårsutdelning AZN 11.99 |
2011-01-27 | Bokslutskommuniké 2010 |
2010-10-28 | Kvartalsrapport 2010-Q3 |
2010-08-04 | Halvårsutdelning AZN 5.12 |
2010-07-29 | Kvartalsrapport 2010-Q2 |
2010-04-29 | Kvartalsrapport 2010-Q1 |
2010-02-03 | Halvårsutdelning AZN 12.43 |
2010-01-28 | Bokslutskommuniké 2009 |
2009-10-29 | Kvartalsrapport 2009-Q3 |
2009-08-05 | Halvårsutdelning AZN 4.41 |
2009-07-30 | Kvartalsrapport 2009-Q2 |
2009-04-30 | Kvartalsrapport 2009-Q1 |
2009-04-30 | Årsstämma 1 |
2009-02-04 | Halvårsutdelning AZN 12.02 |
2008-08-06 | Halvårsutdelning AZN 3.34 |
2008-02-06 | Halvårsutdelning AZN 8.61 |
2007-08-08 | Halvårsutdelning AZN 3.49 |
2007-02-07 | Halvårsutdelning AZN 8.6 |
2006-08-09 | Halvårsutdelning AZN 3.6 |
2006-02-08 | Halvårsutdelning AZN 7.02 |
2005-08-10 | Halvårsutdelning AZN 2.99 |
2005-02-09 | Halvårsutdelning AZN 4.497 |
2004-08-11 | Halvårsutdelning AZN 2.2 |
2004-02-18 | Halvårsutdelning AZN 3.91 |
2003-08-20 | Halvårsutdelning AZN 2.07 |
2003-02-19 | Halvårsutdelning AZN 3.99 |
2002-08-21 | Halvårsutdelning AZN 2.21 |
2002-02-20 | Halvårsutdelning AZN 5.01 |
2001-08-22 | Halvårsutdelning AZN 2.44 |
2001-02-21 | Halvårsutdelning AZN 4.49 |
2000-09-04 | Halvårsutdelning AZN 2.1 |
2000-03-08 | Halvårsutdelning AZN 4.01 |
1999-09-06 | Halvårsutdelning AZN 1.89 |
1999-04-01 | Split AZN 1:0.5045 |
1997-05-26 | Split AZN 1:2 |
1993-06-14 | Split AZN 1:5 |
1987-06-04 | Split AZN 1:2 |
Beskrivning
Land | Storbritannien |
---|---|
Lista | Large Cap Stockholm |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
Industry leader in Product Delivery
AstraZeneca's top three position in the 2022 Access to Medicine Index (AtMI) (https://bit.ly/news_index22) reflects the Company's leading work to strengthen global health systems, as well as increase equitable and affordable patient access to life-changing treatments.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "We believe it's vital everyone has access to affordable, sustainable, and innovative healthcare, particularly in low- and middle-income countries. This ranking reflects AstraZeneca's strategic focus on improving access to medicines and to the crucial work with our partners to strengthen health system resilience."
AtMI is an independent ranking of 20 of the world's largest pharmaceutical companies and evaluates their impact on improving access to medicine in low- and middle-income countries (LMICs). It focuses on three technical areas: Governance of Access; Research and Development (R&D); and Product Delivery. AstraZeneca moved up from 7[th] to 3[rd] position after performing well across all three technical areas.
AstraZeneca was recognised by AtMI as the industry leader in Product Delivery, noting its application of tailored access strategies for different countries reflecting their income classifications across all product categories. The Company's approach to patent transparency and sharing of intellectual property assets, using technology transfers, was also highlighted as key to ensuring continuous supply of medicines in LMICs. Furthermore, the AtMI recognised AstraZeneca's local capacity building initiatives and use of inclusive business models aimed at meeting the access needs of populations at the base of the income pyramid.
AstraZeneca also performed well in the Governance of Access category reflecting robust compliance controls, and also in R&D for its access plans for projects in Phase 2 or 3 of clinical development. Ongoing company initiatives to support access to COVID-19 vaccines via manufacturing, procurement, and distribution agreements in the light of the pandemic were also recognised.
Read more about the delivery of AstraZeneca's Access to healthcare commitments in the 2021 Sustainability Report (https://www.astrazeneca.com/content/dam/az/Sustainability/2022/pdf/Sustainability_Report_2021.pdf) and Sustainability Data Summary (https://www.astrazeneca.com/content/dam/az/Sustainability/2022/pdf/Sustainability_Data_Summary_2021.pdf).
Notes
Access to Medicine Index
The Access to Medicine Index is the longest-running assessment of the pharmaceutical industry's actions to improve access to medicine in low- and middle-income countries (LMICs). It ranks the companies, tracks progress, identifies best practice, and demonstrates where action is urgently needed to improve access to medicine for some of the world's most vulnerable populations.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).
Contacts
For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).